Why is the ResApp share price lifting today?

Progress on a takeover bid for the company has been announced.

Key points
  • Shareholders have given the green light on a takeover proposal from Pfizer
  • The court must approve it for the deal to proceed
  • The deal is expected to close on the 23rd of September

The ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest news on Pfizer's proposed takeover bid.

Shares in the ASX healthcare company are up 0.98%, trading at 21 cents at the time of writing after shareholders yesterday approved the scheme of arrangement for Pfizer to acquire 100% of ResApp's shares.

ResMed advised the next step of the takeover process would involve a second court hearing at the Supreme Court of New South Wales to be held on Tuesday next week.

For the bid to be accepted, the Supreme Court must first approve it on the condition that it's in the best interest of ResApp shareholders. Also, any remaining conditions must be either satisfied or waived before the hearing.

If these conditions are met, the deal is expected to complete on 23 September. The last date that ResApp shares will trade on the ASX will be Wednesday, 14 September.

Pfizer upgraded its bid to 20.8 cents per share on Saturday last week, up from 14.6 cents per share.

That puts ResApp's valuation in the $198.8 million ballpark at the time of writing.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

ResApp share price snapshot

The ResApp share price is up a stunning 195.7% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down 10.77% over the same period.

The company's market capitalisation is $178.3 million at the time of writing.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »